GSK reports 3-share CEO purchase; stock pre-market at EUR 21.06
Published on 10/13/2026 at 08:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- GSK CEO Luke Miels acquired three ordinary shares under the company's Share Reward Plan.
- ViiV Healthcare announced an Axmed distribution agreement covering more than 50 middle-income countries.
- GSK stock was at EUR 21.06 pre-market at Lang & Schwarz on October 13, 2026.
GSK disclosed a three-share purchase by CEO Luke Miels under its Share Reward Plan on October 12, 2026. Separately, GSK stock was at EUR 21.06 at Lang & Schwarz at 8:47 a.m. CEST on October 13, 2026.
Pre-market trading
The Lang & Schwarz quote showed a bid of EUR 21.02 and an ask of EUR 21.10. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of GSK stock.
Director share-plan purchase
The filing identified GSK plc as the issuer and said Luke Miels, the company's chief executive officer, acquired three ordinary shares at GBP 17.5852 each on October 8, 2026, following the reinvestment of dividends through the Share Reward Plan. The transaction was reported on October 12, 2026. Refinitiv carried the regulatory notification.
ViiV expands distribution access
ViiV Healthcare, which is majority owned by GSK, announced on October 12, 2026, that it had appointed Axmed as a non-exclusive distributor for ViiV Healthcare HIV medicines in more than 50 middle-income countries, subject to applicable local regulatory requirements. ViiV Healthcare said the arrangement is intended to give local governments and healthcare institutions a simpler route to procure the medicines.
Market context: Market report FTSE 100.
